Novo’s Ozempic, Wegovy listed as available by FDA, STAT reports

All doses of Novo Nordisk’s (NVO) diabetes and obesity treatments are listed as available on the FDA’s drug shortage list as of Wednesday, raising the possibility that the medications could soon be taken off the list entirely, a development that could affect compounding pharmacies and patients relying on compounded drugs, STAT’s Elaine Chen reports. Semaglutide has been on the shortage list for over two years, Chen notes. A spokesperson for the FDA says the agency is looking to determine whether the demand for the drug, the scientific name for Ozempic and Wegovy, exceeds supply.